Shares of pSivida Corp. (NASDAQ:PSDV) have received an average recommendation of “Buy” from the eight analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $7.67.
PSDV has been the subject of several recent research reports. Northland Securities reissued a “buy” rating and issued a $10.00 price target on shares of pSivida in a research report on Monday, December 11th. Laidlaw initiated coverage on shares of pSivida in a research report on Wednesday, November 8th. They issued a “buy” rating and a $5.00 price target for the company. HC Wainwright set a $5.00 price target on shares of pSivida and gave the stock a “buy” rating in a research report on Wednesday, October 11th. ValuEngine cut shares of pSivida from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Finally, B. Riley set a $5.00 price objective on shares of pSivida and gave the stock a “buy” rating in a research note on Monday, December 4th.
A hedge fund recently bought a new stake in pSivida stock. OxFORD Asset Management LLP purchased a new stake in shares of pSivida Corp. (NASDAQ:PSDV) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned about 0.18% of pSivida at the end of the most recent reporting period. 9.70% of the stock is currently owned by institutional investors and hedge funds.
pSivida (NASDAQ:PSDV) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.15). pSivida had a negative net margin of 226.31% and a negative return on equity of 139.56%. The firm had revenue of $0.39 million during the quarter, compared to analyst estimates of $0.74 million. equities research analysts anticipate that pSivida will post -0.59 earnings per share for the current fiscal year.
WARNING: This article was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/22/psivida-corp-psdv-given-average-recommendation-of-buy-by-analysts.html.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.